Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Tablet Health vs VyrarX

Tablet Health
Graded #495

Lower grade

vs+20.699999999999996
VyrarX
Graded #155

Higher grade

The verdict

VyrarX takes it — 68.3/100 to 47.6/100.

VyrarX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, prescribed by licensed US physicians.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVyrarX +15
45
60
Dose & formulationVyrarX +13
51
64
Clinical oversightVyrarX +47
37
84
Labs & monitoringVyrarX +22
50
72
FulfillmentVyrarX +14
57
71
Contract termsEven
55
55
Tablet Health · left barVyrarX · right bar

The numbers

MetricTablet HealthVyrarX
WeighScore47.6/10068.3/100
GradeCC
Scorecard rank#495#155
SemaglutideNot disclosed$179/mo (starting dose, compounded)
TirzepatideNot disclosed$329/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
VyrarX

Graded #155 · C

Strengths

  • LegitScript certified with active seal (ID 51177727)
  • Semaglutide starting at $179/month with free shipping included
  • 1:1 direct provider messaging and personalized titration plan in every plan
  • Nutrition coaching included with the weight-loss program
  • Provider review completed within 24 hours; no insurance required

Where it loses points

  • Tirzepatide at $329/month starting is at the high end of the compounded market
  • Compounding pharmacy not named on any public page
  • No physician names or clinical leadership disclosed publicly
  • Only 47 states covered — the 3 excluded states are not named on the site
  • Labs not included in the weight-loss plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard